Skip to main content
Top
Published in: BMC Medicine 1/2016

Open Access 01-12-2016 | Commentary

Drug safety: withdrawn medications are only part of the picture

Author: Nigel S. B. Rawson

Published in: BMC Medicine | Issue 1/2016

Login to get access

Abstract

Abstract

In a research article published in BMC Medicine, Onakpoya and colleagues provide a historical review of withdrawals of medications for safety reasons. However, withdrawn medications are only one part of the picture about how regulatory agencies manage drug risks. Moreover, medications introduced before the increased pre-marketing regulations and post-marketing monitoring systems instituted after the thalidomide tragedy have little relevance when considering the present drug safety picture because the circumstances under which they were introduced were completely different. To more fully understand drug safety management and regulatory agency actions, withdrawals should be evaluated within the setting and timeframe in which the medications are approved, which requires information about approvals and safety warnings. Studies are needed that provide a more comprehensive current picture of the identification and evaluation of drug safety risks as well as how regulatory agencies deal with them.
Literature
1.
go back to reference Rawson NSB. Drug therapy: serendipity and science. Can Pharmaceut J. 1990;123:493–502. Rawson NSB. Drug therapy: serendipity and science. Can Pharmaceut J. 1990;123:493–502.
2.
go back to reference The Sunday Times Insight Team. Suffer the children: the story of thalidomide. London: André Deutsch; 1979. The Sunday Times Insight Team. Suffer the children: the story of thalidomide. London: André Deutsch; 1979.
3.
go back to reference Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press; 1986. Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press; 1986.
4.
go back to reference Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.CrossRefPubMedPubMedCentral Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.CrossRefPubMedPubMedCentral
5.
go back to reference Mitchell TD. Calomel considered as a poison. New Orleans Med J. 1844–5;1:28–35. Mitchell TD. Calomel considered as a poison. New Orleans Med J. 1844–5;1:28–35.
6.
go back to reference Bakke OM, Wardell WM, Lasagna L. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin Pharmacol Ther. 1984;35:559–66.CrossRefPubMed Bakke OM, Wardell WM, Lasagna L. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin Pharmacol Ther. 1984;35:559–66.CrossRefPubMed
7.
go back to reference Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58:108–17.CrossRefPubMed Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58:108–17.CrossRefPubMed
8.
go back to reference Rawson NSB, Kaitin KI. Canadian and US drug approval times and safety considerations. Ann Pharmacother. 2003;37:1403–8.CrossRefPubMed Rawson NSB, Kaitin KI. Canadian and US drug approval times and safety considerations. Ann Pharmacother. 2003;37:1403–8.CrossRefPubMed
9.
go back to reference Rawson NSB. New drug approval times and safety warnings in the United States and Canada, 1992–2011. J Popul Ther Clin Pharmacol. 2013;20:e67–81.PubMed Rawson NSB. New drug approval times and safety warnings in the United States and Canada, 1992–2011. J Popul Ther Clin Pharmacol. 2013;20:e67–81.PubMed
13.
go back to reference Niyomnaitham S, Page A, La Caze A, Whitfield K, Smith AJ. Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. BMC Health Serv Res. 2014;14:151.CrossRefPubMedPubMedCentral Niyomnaitham S, Page A, La Caze A, Whitfield K, Smith AJ. Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. BMC Health Serv Res. 2014;14:151.CrossRefPubMedPubMedCentral
14.
15.
go back to reference Cohen A, Rabbani A, Shah N, Alexander GC. Changes in glitazone use among office-based physicians in the US, 2003–2009. Diabetes Care. 2010;33:823–5.CrossRefPubMedPubMedCentral Cohen A, Rabbani A, Shah N, Alexander GC. Changes in glitazone use among office-based physicians in the US, 2003–2009. Diabetes Care. 2010;33:823–5.CrossRefPubMedPubMedCentral
Metadata
Title
Drug safety: withdrawn medications are only part of the picture
Author
Nigel S. B. Rawson
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2016
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-016-0579-5

Other articles of this Issue 1/2016

BMC Medicine 1/2016 Go to the issue